Spots Global Cancer Trial Database for Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Official Title: An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Study ID: NCT03715933
Study Description
Brief Summary: This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Detailed Description:
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute, Scottsdale, Arizona, United States
City of Hope, Duarte, California, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California, United States
Sarcoma Oncology Center, Santa Monica, California, United States
University of Colorado Hospital, Aurora, Colorado, United States
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
The University of Chicago, Chicago, Illinois, United States
Center for Cancer Research at NCI, Bethesda, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
START Midwest Michigan, PC, Grand Rapids, Michigan, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Vanderbilt University School of Medicine, Nashville, Tennessee, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
NEXT Oncology - Virginia, Fairfax, Virginia, United States
Contact Details
Name: Clinical Lead
Affiliation: Inhibrx Biosciences, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
